PTPRJ and idiopathic pulmonary fibrosis: Some extracellular proteins such as SDC2 can bind to PTPRJ and activate its activity, reducing fibrosis levels in vivo as well as in vitro in lung fibrosis models, providing new ideas in the treatment of IPF [30].